Summary
Global Markets Direct’s, ‘Plague - Pipeline Review, H2 2016’, provides an overview of the Plague pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plague and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Plague
- The report reviews pipeline therapeutics for Plague by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Plague therapeutics and enlists all their major and minor projects
- The report assesses Plague therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Plague
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Plague
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plague pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aradigm Corporation
AvidBiotics Corp.
Endacea, Inc.
Grifols, S.A.
iBio, Inc.
Mucosis B.V.
Syntiron LLC
Takeda Pharmaceutical Company Limited
Tetraphase Pharmaceuticals Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Plague Overview 8
Therapeutics Development 9
Pipeline Products for Plague - Overview 9
Pipeline Products for Plague - Comparative Analysis 10
Plague - Therapeutics under Development by Companies 11
Plague - Therapeutics under Investigation by Universities/Institutes 12
Plague - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Plague - Products under Development by Companies 16
Plague - Products under Investigation by Universities/Institutes 17
Plague - Companies Involved in Therapeutics Development 18
Aradigm Corporation 18
AvidBiotics Corp. 19
Endacea, Inc. 20
Grifols, S.A. 21
iBio, Inc. 22
Mucosis B.V. 23
Syntiron LLC 24
Takeda Pharmaceutical Company Limited 25
Tetraphase Pharmaceuticals Inc. 26
Plague - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
(plague + small pox) vaccine - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
anthrax + plague vaccine - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
ARD-3100 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ARD-3150 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ciprofloxacin hydrochloride - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
L-97-1 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
plague vaccine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
plague vaccine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
plague vaccine - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
plague vaccine - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
plague vaccine - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
plague vaccine - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
plague vaccine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
plague vaccine 2 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
pneumonic plaque vaccine - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Recombinant Protein for Pneumonic Plague - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
TP-271 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Yersinia pestis vaccine - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Plague - Dormant Projects 65
Plague - Discontinued Products 66
Plague - Product Development Milestones 67
Featured News & Press Releases 67
Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague 67
May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70
List of Tables
Number of Products under Development for Plague, H2 2016 9
Number of Products under Development for Plague - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Comparative Analysis by Unknown Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Plague - Pipeline by Aradigm Corporation, H2 2016 18
Plague - Pipeline by AvidBiotics Corp., H2 2016 19
Plague - Pipeline by Endacea, Inc., H2 2016 20
Plague - Pipeline by Grifols, S.A., H2 2016 21
Plague - Pipeline by iBio, Inc., H2 2016 22
Plague - Pipeline by Mucosis B.V., H2 2016 23
Plague - Pipeline by Syntiron LLC, H2 2016 24
Plague - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 25
Plague - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Assessment by Combination Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Plague - Dormant Projects, H2 2016 65
Plague - Discontinued Products, H2 2016 66
List of Figures
Number of Products under Development for Plague, H2 2016 9
Number of Products under Development for Plague - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Targets, H2 2016 29
Number of Products by Stage and Targets, H2 2016 29
Number of Products by Mechanism of Actions, H2 2016 31
Number of Products by Stage and Mechanism of Actions, H2 2016 31
Number of Products by Routes of Administration, H2 2016 33
Number of Products by Stage and Routes of Administration, H2 2016 33
Number of Products by Molecule Types, H2 2016 35
Number of Products by Stage and Molecule Types, H2 2016 35
